Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak

BMC Pulmonary Medicine, Journal Year: 2024, Volume and Issue: 24(1)

Published: March 27, 2024

Abstract Background Chronic cough is a common symptom in patients post the coronavirus disease 2019 (COVID-19). In this study, we aimed to investigate efficacy of inhaled corticosteroids (ICS) and clinical characteristics with post-COVID-19 chronic during Omicron era. Methods An ambispective, longitudinal cohort study was conducted that included who attended respiratory clinic at our hospital between January 1, 2023, March 31, 2023 complaint persistent lasting more than 8 weeks. At 30 60 days after first visit for cough, enrolled were prospectively followed up. We compared changes symptoms pulmonary function receiving ICS treatment (ICS group) those not (NICS two visits. Results A total 104 group, n = 51; NICS 53). The most accompanying sputum (58.7%, 61/104) dyspnea (48.1%, 50/104). Seventy-one (82.6%, 71/86) had airway hyperresponsiveness, 49 (47.1%, 49/104) newly diagnosed asthma. Most (95.2%, 99/104) exhibited improvement visit. parameters group significantly improved baseline values ( P < 0.05), FEV 1 /FVC greater 0.003) days. Conclusions Severe acute syndrome coronavirus-2 (SARS-CoV-2) may contribute pathogenesis asthma, which could be underlying cause infection. Post-COVID-19 era often accompanied by sputum, dyspnea, hyperresponsiveness. did have significant impact on management cough; however, it can improve impaired lung these individuals.

Language: Английский

---

Long-term symptoms after SARS-CoV-2 infection in a cohort of people living with HIV

Infection, Journal Year: 2024, Volume and Issue: unknown

Published: May 3, 2024

Abstract Background Our Hospital in Northern Italy assists 3817 people living with HIV (PLWH) and has faced the impact of COVID-19. Little is known about infection on risk post-COVID-19 conditions (PCCs) onset. We aim to assess incidence PCC PLWH factors associated its occurrence. Methods performed a retrospective, observational study including all > 18 years registered Brescia Health Protection Agency database, assessing SARS-CoV-2 burden, vaccination status, socio-demographic, viro-immunological parameters from February 2020 until May 2022. Persistence self-reported symptoms (clustered into gastrointestinal, respiratory, osteo-muscular, neuro-behavioral symptoms) was evaluated after 3 months by telephone-administered questionnaire. estimated associations between variables outcomes through univariate multivariable logistic models. Results In period, 653 were diagnosed (17.1%). observed 19 (2.9%) reinfections, 71 (10.9%) hospitalizations, (0.5%) deaths. interviewed 510/653 (78%), 178 (PCCs prevalence 34.9%; CI 95% 30.7–39.2) reported persistent symptoms. Asthenia/fatigue most symptom (60/178), followed muscular pain (54/178). multivariate regression model, there lower PCCs males respect females (adjusted OR = 0.64; 0.99–3.66), while hospitalization during acute an increased 1.9; 0.99–3.66). Notably, no variable modified Conclusions highlights substantial among PLWH, three post-SARS-CoV-2 infection, independent features or status.

Language: Английский

---

Long COVID Prevalence and the Impact of the Third SARS-CoV-2 Vaccine Dose: A Cross-Sectional Analysis from the Third Follow-Up of the Borriana Cohort, Valencia, Spain (2020–2022)

Vaccines, Journal Year: 2023, Volume and Issue: 11(10), P. 1590 - 1590

Published: Oct. 12, 2023

In March 2020, a COVID-19 outbreak linked to mass gathering dinners at the Falles Festival in Borriana, Spain, resulted an estimated attack rate of 42.6% among attendees.In June 2022, we conducted cross-sectional follow-up study 473 adults aged 18 64 who attended examining cumulative experience after SARS-CoV-2 infection and vaccination responses. Data included demographic details, lifestyle habits, medical history, records, vaccinations from population-based vaccine registry. Blood samples were analyzed for antibodies cellular immunity. We employed doubly robust inverse-probability weighting analysis estimate booster dose's impact on long COVID prevalence symptom count.A total 28.1% participants met WHO criteria COVID, with older individuals showing higher rates. Long diagnosis was less likely factors including O blood group, occupational status, physical activity, three doses, strong SARS-CoV-2-S-reactive IFNγ-producing-CD8+ response, during Omicron period. Increased age, high or low social underlying health conditions, severe initial episode, reinfection associated likelihood. A dose, compared one two reduced risk by 74% (95% CI: 56% 92%) count 55% 32% 79%).Long prevalent significant portion those contracted COVID-19, underscoring need sustained therapeutic strategies. Vaccinations, notably had substantial beneficial effect long-term outcomes, affirming vaccination's role mitigating consequences.

Language: Английский

---

Long COVID Prevalence and the Impact of the Third SARS-CoV-2 Vaccine Dose: A Cross-Sectional Analysis from the Third Follow-Up of the Borriana Cohort, Valencia, Spain (2020-2022)

Published: Sept. 1, 2023

Background: In March 2020, a COVID-19 outbreak associated with the Falles Festival in Borriana, Spain, led to significant infections. Methods: June 2022, we conducted cross-sectional follow-up study of 473 socially engaged adults aged 18 64, examining cumulative experience after SARS-CoV-2 infection and vaccination responses. Data included demographic details, lifestyle habits, medical history, records, vaccinations from population-based vaccine registry. Blood samples were analyzed for antibodies cellular immunity. We employed doubly robust inverse weighted probability analysis estimate booster dose&#039;s impact on long COVID prevalence symptom count. Results: 28.1% participants met WHO criteria COVID, older individuals showing higher rates. Not complying factors including O blood group, occupational status, physical activity, three doses, strong SARS-CoV-2-S-reactive IFNγ‐producing‐CD8+ response, during Omicron period. Conversely, increased age, high or low social underlying health conditions, severe initial episode, reinfection likelihood. A dose, compared one two reduced risk by 74% (95% CI: 56.4% 91.7%) count 55.2% 31.6% 78.7%). Conclusion: Long was prevalent portion those who contracted COVID-19, underscoring need sustained therapeutic strategies. Vaccinations, notably had substantial beneficial effect long-term outcomes, affirming vaccination’s role mitigating consequences.

Language: Английский

---

COVID-19 and Gastrointestinal Tract: From Pathophysiology to Clinical Manifestations

Medicina, Journal Year: 2023, Volume and Issue: 59(10), P. 1709 - 1709

Published: Sept. 24, 2023

Background: Since its first report in Wuhan, China, December 2019, COVID-19 has become a pandemic, affecting millions of people worldwide. Although the virus primarily affects respiratory tract, gastrointestinal symptoms are also common. The aim this narrative review is to provide an overview pathophysiology and clinical manifestations COVID-19. Methods: We conducted systematic electronic search English literature up January 2023 using Medline, Scopus, Cochrane Library, focusing on papers that analyzed role SARS-CoV-2 tract. Results: Our highlights directly infects tract can cause such as diarrhea, nausea/vomiting, abdominal pain, anorexia, loss taste, increased liver enzymes. These result from mucosal barrier damage, inflammation, changes microbiota composition. exact mechanism how overcomes acid gastric environment leads intestinal damage still being studied. Conclusions: vaccination prevalence less severe symptoms, long-term interaction with remains concern. Understanding interplay between essential for future management virus.

Language: Английский

---